France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a revenue growth strategy in oncology and neurology. The deal brings an Edgewise drug in clinical development for two rare neuromuscular disorders with limited treatment options.
The post Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics appeared first on MedCity News.
